BR0307951A - Co-terapia para o tratamento de enxaqueca compreendendo derivados de anticonvulsivantes e agentes antienxaqueca - Google Patents

Co-terapia para o tratamento de enxaqueca compreendendo derivados de anticonvulsivantes e agentes antienxaqueca

Info

Publication number
BR0307951A
BR0307951A BR0307951-1A BR0307951A BR0307951A BR 0307951 A BR0307951 A BR 0307951A BR 0307951 A BR0307951 A BR 0307951A BR 0307951 A BR0307951 A BR 0307951A
Authority
BR
Brazil
Prior art keywords
migraine
therapy
treatment
agents
anticonvulsant
Prior art date
Application number
BR0307951-1A
Other languages
English (en)
Inventor
Ian R Livinsgstone
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of BR0307951A publication Critical patent/BR0307951A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"CO-TERAPIA PARA O TRATAMENTO DE ENXAQUECA COMPREENDENDO DERIVADOS DE ANTICONVULSIVANTES E AGENTES ANTIENXAQUECA". A presente invenção refere-se a um método para o tratamento e /ou prevenção de enxaqueca e sintomas associados (náusea, vómito, fotofobia, fonofobia, etc.) compreendendo co-terapia com uma quantidade terapeuticamente eficaz de um ou mais agentes antienxaqueca e um ou mais derivados de anticonvulsivante.
BR0307951-1A 2002-02-26 2003-02-25 Co-terapia para o tratamento de enxaqueca compreendendo derivados de anticonvulsivantes e agentes antienxaqueca BR0307951A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35989402P 2002-02-26 2002-02-26
PCT/US2003/005463 WO2003072138A1 (en) 2002-02-26 2003-02-25 Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents

Publications (1)

Publication Number Publication Date
BR0307951A true BR0307951A (pt) 2004-12-21

Family

ID=27663315

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307951-1A BR0307951A (pt) 2002-02-26 2003-02-25 Co-terapia para o tratamento de enxaqueca compreendendo derivados de anticonvulsivantes e agentes antienxaqueca

Country Status (19)

Country Link
US (2) US20030225002A1 (pt)
EP (1) EP1478400A1 (pt)
JP (1) JP2005518439A (pt)
KR (1) KR101008326B1 (pt)
CN (1) CN100352506C (pt)
AU (1) AU2003213242A1 (pt)
BR (1) BR0307951A (pt)
CA (1) CA2419989A1 (pt)
HK (1) HK1080731A1 (pt)
HR (1) HRP20040846A2 (pt)
IL (2) IL163720A0 (pt)
MX (1) MXPA04008259A (pt)
NO (1) NO20043984L (pt)
NZ (1) NZ534874A (pt)
PL (1) PL372393A1 (pt)
RU (1) RU2004126093A (pt)
UA (1) UA81110C2 (pt)
WO (1) WO2003072138A1 (pt)
ZA (1) ZA200407729B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
WO2005079787A1 (en) * 2004-02-17 2005-09-01 Sepracor Inc. Treatment or prophylaxis of migraine or headache disorders using citalopram, escitalopram or citalopram metabolites
US20060233892A1 (en) * 2005-04-19 2006-10-19 Curt Hendrix Topiramate compositions for treatment of headache
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
FR2890564B1 (fr) * 2005-09-09 2007-10-19 Servier Lab Nouvelle association entre l'agomelatine et un inhibiteur de la recapture de la noradrenaline et les compositions pharmaceutiques qui la contiennent
CN104138634B (zh) * 2006-04-13 2016-09-07 梯瓦制药国际有限责任公司 递送抗偏头痛化合物的透皮方法和系统
US20100016363A1 (en) * 2006-04-25 2010-01-21 Kowa Pharmaceuticals America, Inc. Fixed Combination Dosage Forms for the Treatment of Migraine
US9744137B2 (en) 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
SI2124556T1 (sl) 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Farmacevtske sestave
ES2312308T3 (es) 2006-11-17 2013-03-26 Supernus Pharmaceuticals, Inc. Formulaciones de liberación sostenida de topiramato
AU2007329373B2 (en) * 2006-12-04 2013-06-20 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
EP3090743A1 (en) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
CN102164603B (zh) * 2008-09-17 2015-11-25 麦克莱恩医院 用于治疗丛集性头痛症的方法和试剂盒
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2017152130A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
WO2018067330A1 (en) * 2016-10-06 2018-04-12 Baylor College Of Medicine Photochromatic modulation with fluorescein for the treatment of photo-oculodynia and blepharospasm
DK3955933T3 (da) * 2019-04-15 2024-02-12 Vistagen Therapeutics Inc Behandling af migræne

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
AU651244B2 (en) * 1991-09-19 1994-07-14 Mcneilab, Inc. Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US5998380A (en) * 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
ES2241055T3 (es) * 1996-08-23 2005-10-16 Endo Pharmaceuticals Inc Composicion que contiene un anticonvulsionante para tratar el dolor neuropatico.
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US20020015713A1 (en) * 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
CA2283122A1 (fr) * 1997-03-03 1998-09-11 Laboratoires Remilea Compositions d'extraits de plantes, leur procede de preparation, et compositions pharmaceutiques les renfermant
US5855907A (en) * 1997-03-24 1999-01-05 Peyman; Gholam A. Method of treatment of migraine
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
US5935933A (en) * 1997-07-16 1999-08-10 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating neuropathic pain
GB9720270D0 (en) * 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
US6068999A (en) * 1998-06-25 2000-05-30 Hendrix; Curt Dietary supplement for supporting cerebrovascular tone and treating migraine headaches
DK1143967T3 (da) * 1999-01-19 2005-01-10 Ortho Mcneil Pharm Inc Anticonvulsive derivater egnede til behandling af Hortons hovedpine
AU782759B2 (en) * 1999-08-20 2005-08-25 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug

Also Published As

Publication number Publication date
US20070099849A1 (en) 2007-05-03
HRP20040846A2 (en) 2005-06-30
ZA200407729B (en) 2006-06-28
WO2003072138A1 (en) 2003-09-04
RU2004126093A (ru) 2005-04-10
HK1080731A1 (en) 2006-05-04
UA81110C2 (en) 2007-12-10
IL163720A (en) 2012-06-28
PL372393A1 (en) 2005-07-25
AU2003213242A1 (en) 2003-09-09
NZ534874A (en) 2007-03-30
CN100352506C (zh) 2007-12-05
JP2005518439A (ja) 2005-06-23
CN1646168A (zh) 2005-07-27
MXPA04008259A (es) 2005-05-27
US20030225002A1 (en) 2003-12-04
NO20043984L (no) 2004-09-23
CA2419989A1 (en) 2003-08-05
IL163720A0 (en) 2005-12-18
KR20040091074A (ko) 2004-10-27
EP1478400A1 (en) 2004-11-24
KR101008326B1 (ko) 2011-01-13

Similar Documents

Publication Publication Date Title
BR0307951A (pt) Co-terapia para o tratamento de enxaqueca compreendendo derivados de anticonvulsivantes e agentes antienxaqueca
UY24354A1 (es) Composiciones farmacéuticas que contienen epinastina
BR0314690A (pt) Goma de mascar revestida
BR0310092A (pt) Combinação de compostos orgânicos
BR0313282A (pt) Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia
BR9913288A (pt) Composição antioxidante compreendendo acetil l-carnitina e ácido alfa-lipóico
WO2004089353A8 (en) Methods for treatment of parkinson's disease
EA200500250A1 (ru) Аналоги тиомолибдата и их применение
RS52780B (en) MEANS OF PREVENTION AND TREATMENT OF DISORDERS CONCERNING MODULATION OF RYR RECEPTORS
EA200601746A1 (ru) Применение ротиготина для лечения и предупреждения синдрома "паркинсонизм-плюс"
BR0115411A (pt) Combinações sinergìsticas compreendendo um inibidor de renina para doenças cardiovasculares
BR9911440A (pt) Composição para a prevenção e/ou tratamento de osteoporose e alterações devido à sìndrome de menopausa
RS20050392A (en) Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
BR0316238A (pt) Quimioterapia de associação compreendendo um inibidor de mek e capecitabina para tratamento de câncer
WO2005110417A8 (en) Phycotoxins and uses thereof
NO20060242L (no) Kombinasjonen av en serotonin-reopptaksinhibitor og agomelatin
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
NO20033665D0 (no) Azoler som malonyl-CoA-dekarboksylaseinhibitorer som er anvendbare som metaboliske modulatorer
BR0211063A (pt) Sais de derivados anticonvulsivantes
BR0210013A (pt) Gel oftálmico de pirenzepina
BR0315355A (pt) Método para o tratamento ou prevenção de sintomas de vasomotores em um paciente, composição farmacêutica e utilização de um inibidor de re-apreensão de norepinefrina
BR0316163A (pt) Inibidores de histona desacetilase para tratamento de doenças degenerativas do olho
BR9916807A (pt) Antagonistas de 5ht1 para terapia antidepressiva
BR0309406A (pt) Composição farmacêutica, processo de preparação, kit e métodos para tratamento de obesidade, utilização de composição e inibidor de lìpases, inibidor de lìpáses e glucomanan ou konjac e utilização dos mesmos e método de tratamento

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.